Brent crude losses quickly widened to 1.3%, now trading at $95.84/bbl.

The Shanghai Municipal Food and Drug Safety Commission issued a 15th Five-Year Plan to ensure drug safety and promote high-quality pharmaceutical development, outlining multiple regulatory reforms. It will deepen clinical-trial review and approval reforms for innovative drugs and support R&D. The plan calls for reforming review and approval procedures for supplemental applications for domestic and overseas chemical drug production and offering front-end support for major change filings on local chemical drugs. Shanghai will seek pilot programs for dossier-based review of generics to accelerate first-to-market generics, streamline post-approval change processes, pilot continuous manufacturing technologies, and optimize temporary import procedures for clinically urgent medicines.

Shanghai Gold Exchange gold T+D was up 1.17% at 882.28 yuan/gram in early trade on Monday, Nov. 9; silver T+D was up 2.21% at 12,691.0 yuan/kg.